13339-01-0

Usage

Uses

Used in Pharmaceutical Research:
1-(2-Ethoxyphenyl)piperazine is used as a research compound for its potential in developing drugs that address neurological conditions. Its serotonin antagonist properties make it a promising candidate for exploring treatments for disorders such as depression and anxiety.
Used in Drug Development:
In the pharmaceutical industry, 1-(2-Ethoxyphenyl)piperazine is utilized as a starting point for the synthesis of new drugs, with the aim of creating medications that can effectively manage a range of neurological disorders. 1-(2-Ethoxyphenyl)piperazine's interaction with serotonin receptors is a key area of focus in this application, as it may lead to the development of novel therapeutics with improved efficacy and safety profiles.

Upstream product

• 43204-63-3 bis(2-bromoethyl)amine hydrobromide 
• 94-70-2 ortho-phenitidine 
• 83081-75-8 1-(2-ethoxyphenyl)piperazine monohydrochloride 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Downstream Products

• 137965-77-6 1-{5-[4-(2-Ethoxy-phenyl)-piperazin-1-ylmethyl]-1-methyl-1H-pyrrol-2-ylmethyl}-pyrrolidin-2-one 
• 74760-01-3 1-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-3-(3,4,5-trimethoxy-phenoxy)-propan-2-ol 
• 103247-57-0 2-[4-(2-Ethoxy-phenyl)-piperazin-1-yl]-N-(7-hydroxy-2,2,4,6-tetramethyl-indan-1-yl)-acetamide 
• 135561-99-8 4-(3,5-Dimethyl-pyrazol-1-yl)-1-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-5H-pyridazino[4,5-b]indole 
• 118778-76-0 1-<3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy>-3-<4-(2-ethoxyphenyl)-1-piperazinyl>-2-propanol 
• 83472-27-9 1-[4-(2-Ethoxy-phenyl)-piperazin-1-yl]-3-(3,7,7-trimethyl-5,9-dihydro-6,8-dioxa-2-aza-benzocyclohepten-4-yloxy)-propan-2-ol 
• 83100-00-9 2-<3-<4-(2-ethoxyphenyl)-1-piperazinyl>butyryl>-1,2,3,4,6,7,8,9-octahydrobenzo<1,6>naphthyridine 
• 72572-01-1 5-{3-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-propoxy}-3,4-dihydro-1H-quinolin-2-one 
• 72723-10-5 7-{3-[4-(2-ethoxy-phenyl)-piperazin-1-yl]-propoxy}-3,4-dihydro-1H-quinolin-2-one 

Relevant academic research and scientific papers

Arylpiperazines displaying preferential potency against chloroquine-resistant strains of the malaria parasite Plasmodium falciparum

Arylpiperazines in which the terminal secondary amino group is unsubstituted were found to display a mefloquine-type antimalarial behavior in being significantly more potent against the chloroquine-resistant (W2 and FCR3) strains of Plasmodium falciparum than against the chloroquine-sensitive (D10 and NF54) strains. Substitution of the aforementioned amino group led to a dramatic drop in activity across all strains as well as abolition of the preferential potency against resistant strains that was observed for the unsubstituted counterparts. The data suggest that unsubstituted arylpiperazines are not well-recognized by the chloroquine resistance mechanism and may imply that they act mechanistically differently from chloroquine. On the other hand, 4-aminoquinoline-based heteroarylpiperazines in which the terminal secondary amino group is also unsubstituted, were found to be equally active against the chloroquine-resistant and chloroquine-sensitive strains, suggesting that chloroquine cross-resistance is not observed with these two 4-aminoquinolines. In contrast, two 4-aminoquinoline-based heteroarylpiperazines are positively recognized by the chloroquine resistance mechanism. These studies provide structural features that determine the antimalarial activity of arylpiperazines for further development, particularly against chloroquine-resistant strains.

THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula (I), where R1, R2, R3, R4, R5, R5', R6, R7, X, m, and n are described herein.